INJECTABLE BOTULINUM TOXIN METHOS FOR TREATING HEADACHES
Provided is an invention based on methods to treat or prevent headaches with injectable compositions comprising botulinum toxin that may be administered using an injection paradigm that provides botulinum toxin at one or more locations of neuronal activity associated with EEG detectable brain cortical electrical activity to a subject suffering from such malady. Co-therapuetics therewith are also disclosed.
1 . A method of treating or reducing frequency of headaches in an individual in need of treatment, the method comprising:
administering by injection a dose of an injectable botulinum toxin composition using an injection paradigm that provides botulinum toxin at one or more locations of neuronal activity associated with EEG detectable brain cortical electrical activity in the individual to achieve the therapeutic effect following treatment with the botulinum toxin composition;
wherein the botulinum toxin composition comprises a botulinum toxin component and pharmaceutically acceptable diluent suitable for injection; ; and
wherein the total treatment dose of botulinum toxin component administered to the individual is 100 U to 450 U which is administered in one or more injections sites.
2 . The method according to claim 1 , wherein the headache is selected from a post-traumatic headache, a post-craniotomy headache, tension-type headache, cluster headache, and medication-overuse headache.
3 . (canceled)
4 . The method according to claim 2 , wherein the headache is an episodic migraine headache.
5 . The method according to claim 2 , wherein the headache is a chronic migraine headache.
6 . The method according to claim 4 , wherein the episodic migraine headache is a high-frequency episodic migraine.
7 . The method according to claim 1 , wherein the botulinum toxin is of a serotype A.
8 . The method according to claim 7 , wherein the botulinum toxin is of serotype A having a molecular weight of 150 kDa.
9 - 17 . (canceled)
18 . The method according to claim 1 , wherein the injection sites correspond to one or more electrode placement sites selected from Fpz, Fp1, Fp2, F3, F4, F7, F8, T3, T4, C3, C4, A1, A2, P3, P4, T5, T6, O1, O2, GND1, or GND2.
19 . The method according to claim 18 , wherein the injection sites further include sites selected from trapezius muscle or masseter muscle.
20 . The method according to claim 19 , wherein the injection sites further correspond to one or more electrode placement sites selected from Cz, Oz, or Fz.
21 . The method according to claim 20 , wherein the composition is administered at 10 to 25 injection sites.
22 . The method according to claim 21 , wherein the composition is administered to the injection sites consisting of Fp1, Fp2, T3, T4, T5, T6, O1, O2, F3, F4, P3, P4, F7, F8, GND1, GND2, and Fpz.
23 . The method according to claim 21 , wherein the composition is administered to the injection sites consisting of Fp1, Fp2, T3, T4, T5, T6, O1, O2, F3, F4, P3, P4, F7, F8, GND1, GND2, Fpz, and right and left trapezius muscle.
24 . The method according to claim 21 , wherein the composition is administered to the injection sites consisting of Fp1, Fp2, T3, T4, T5, T6, O1, O2, F3, F4, P3, P4, F7, F8, GND1, GND2, Fpz, trapezius muscles, and masseter muscles.
25 . (canceled)
26 . The method according to claim 22 , wherein the total treatment dose of botulinum toxin component administered to the individual is 300 U to 450 U.
27 . The method according to claim 23 , wherein the total treatment dose of botulinum toxin component administered to the individual is 300 U to 450 U .
28 . (canceled)
29 . The method according to claim 24 , wherein the total treatment dose of botulinum toxin component to the individual is 300 U to 450 U.
30 . (canceled)
31 . (canceled)
32 . The method for use according to claim 1 , wherein the injection volume for one injection site is from 100 to 400 µL.
33 - 38 . (canceled)
39 . The method according to claim 1 , further comprising administering to the individual a co-therapeutic, wherein the co-therapeutic is a CGRP antagonist and the CGRP-antagonist is an anti-calcitonin gene-related peptide receptor antibody (anti-CGRP antibody) or an antigen-binding fragment thereof or a gepant.
40 . The method according to claim 39 , wherein the CGRP-antigonist is an anti-CGRP antibody selected from galcanezumab, fremanezumab, eptinezumab, erenumab, and combinations thereof.
41 . The method according to claim 39 , wherein the CGRP-antagonist is a gepant.
42 . (canceled)
43 . The method according to claim 39 , wherein the CGRP-antagonist is administered sequentially, with the injectable botulinum toxin composition.
44 . The method according to claim 39 , wherein the individual is a non-responder or insufficient responder to one or more triptan drugs.
45 . The method according to claim 1 , further comprising administering to the individual a 5-HT-1F receptor agonist.
46 . The method according to claim 45 , wherein the 5-HT-1F receptor agonist is a ditan or a pharmaceutically-acceptable salt thereof.
47 . (canceled)
48 . The method according to claim 45 , wherein the injectable botulinum toxin composition, are administered separately,sequentially, or simultaneously.
49 . The method according to claim 38 , further comprising administering to the individual an ergot compound.
50 . (canceled)
51 . (canceled)
52 . The method according to claim 22 , wherein the total treatment dose of botulinum toxin component administered to the individual is 200 U to 300 U.
53 . The method according to claim 23 , wherein the total treatment dose of botulinum toxin component administered to the individual is 200 U to 300 U.
54 . The method according to claim 24 , wherein the total treatment dose of botulinum toxin component administered to the individual is 200 U to 300 U.